F2RL1 and cancer: Given that recent epidemiologic studies estimates that 5–7% of the population in western societies will be affected by one of IMIDs conditions and that a steady increase in this incidence is predicted67,68, the identification and the development of potent and selective inhibitors of PAR2 signaling pathways such as I-287 could therefore represent a promising therapeutics for the treatment of inflammation and nociception caused by inflammation, cancer, or injury.